The journey in diagnosis and treatment, from pituitary adenoma to aggressive pituitary tumors
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
https://link.springer.com/content/pdf/10.1007/s11154-020-09561-w.pdf
Reference16 articles.
1. Ho KKY, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, et al. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement. Pituitary. 2019;22(6):569–73. https://doi.org/10.1007/s11102-019-00988-2.
2. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7(5):257–66. https://doi.org/10.1038/nrendo.2011.40.
3. Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K. Aggressive pituitary adenomas–diagnosis and emerging treatments. Nat Rev Endocrinol. 2014;10(7):423–35. https://doi.org/10.1038/nrendo.2014.64.
4. Donoho DA, Bose N, Zada G, Carmichael JD. Management of aggressive growth hormone secreting pituitary adenomas. Pituitary. 2017;20(1):169–78. https://doi.org/10.1007/s11102-016-0781-7.
5. Hernandez-Ramirez LC, Gabrovska P, Denes J, Stals K, Trivellin G, Tilley D, et al. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab. 2015;100(9):E1242-54. https://doi.org/10.1210/jc.2015-1869.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Identification of HSPD1 as a novel invasive biomarker associated with mitophagy in pituitary adenomas;Translational Oncology;2024-03
2. Quantitative proteomics identified a novel invasion biomarker associated with EMT in pituitary adenomas;Frontiers in Endocrinology;2023-03-03
3. Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas;Frontiers in Surgery;2022-06-21
4. Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone;Journal of Oncology;2022-03-21
5. The Role of MicroRNAs in Therapeutic Resistance of Malignant Primary Brain Tumors;Frontiers in Cell and Developmental Biology;2021-10-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3